ZLDI-8
ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.ZLDI-8; it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins. ZLDI-8 treatment enhanced the susceptibility of HCC cells to a small molecular kinase inhibitor Sorafenib, and chemotherapy agents Etoposide and Paclitaxel. ZLDI-8 treatment enhanced the effect of Sorafenib on inhibiting tumor growth in nude HCC-bearing mice model. In nude HCC-bearing mice model, ZLDI-8 (0.2-2 mg/kg; intraperitoneal injection; every two days; for 20 days; nude mice) treatment enhances the effect of Sorafenib on inhibiting tumor growth.
Product Specifications
CAS Number
667880-38-8
Purity
>98% (HPLC)
Solubility
DMSO:62.5 mg/mL (144.17 mM; Need ultrasonic)
Smiles
O=C (/C (C (N1) =O) =C/C2=C (C) N (CCOC3=CC=C (C) C=C3C) C4=C2C=CC=C4) NC1=S
Molecular Formula
C24H23N3O3S
Molecular Weight
433.52
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
AIMP1 (Aminoacyl tRNA synthetase complex-interacting multifunctional protein 1)
Recombinant Mycobacterium Ulcerans hemH Protein (aa 1-340)